Pulmonx reports Q2 EPS (38c), consensus (40c)

Reports Q2 revenue $23.86M, consensus $23.47M. Steve Williamson, president and CEO of Pulmonx (LUNG), commented, “Strong international performance drove double-digit growth and provided a solid foundation for the quarter. While we are revising full-year guidance to reflect longer-than-expected revenue conversion from our U.S. initiatives, we are seeing early signs of traction. Our efforts to build a scalable ecosystem by improving patient identification, access, and engagement, are beginning to deliver results and position us for sustained, long-term growth.”